UK Biotech VC Hits Record £2.8bn With Quarter Still to Run

UK biotech has already raised a record-breaking £2.8bn in venture capital in 2026 — more than any full year between 2022 and 2025 — with a full quarter still left on the clock. That's the headline from a new BioIndustry Association (BIA) report, which puts the sector on track for its best year since 2021.

The third quarter alone shows the acceleration. Total equity raised by UK biotech shot up 113% year-on-year, from £198m in Q3 2025 to £421m ($563m) in Q3 2026. Venture capital landed by British biotechs came in at £270m ($361m), up 44% on the same quarter a year earlier.

The quarter looks smaller than Q2, and the BIA explains why. Q2 pulled in £2.05bn, a figure largely carried by Isomorphic Labs' £1.6bn Series B. The BIA says the Q3 drop tracked broader UK venture trends: VC from all sectors flowing into the country fell by $3.2bn.

The biggest deal of the recent stretch came from Basecamp Research, an AI-powered biotech that raised $104m in a Series C to train its next-generation models and push its pipeline of medicines toward the clinic.

Where does the UK stand in Europe?

Britain remains Europe's top destination for biotech VC. UK companies captured 26% of the European total, which stood at £1.1bn overall. The report also flags NVIDIA's expanding partnerships with UK-based AI biology companies as evidence of the region's role in global collaboration.

The takeaway: UK biotech isn't just recovering — it's out-raising every European peer.

Why is M&A doing the heavy lifting?

Exits are matching the funding story. Earlier this week, Merck KGaA agreed to buy Silence Therapeutics, a London-based developer of short interfering RNA (siRNA) therapies, for $1.3bn.

That deal caps a run of British biotech acquisitions in 2026:

• January: Amgen acquired Dark Blue Therapeutics for up to $840m
• June: Eli Lilly purchased sleep-drug biotech Centessa Pharmaceuticals for $6.3bn
• July: Novartis paid $1.5bn for antibody-drug conjugate (ADC) developer Myricx Bio

The pattern is hard to miss. Global pharma is paying billion-dollar prices for UK science.

Who is actually banking the returns?

Here's the catch. BIA CEO Chris Molley told Pharmaceutical Technology: "This report demonstrates success in VC as well as covering recent acquisitions in Q2, such as Myricx. Both VC and M&A show world class valuations can be secured by companies. Isomophic and CellCentric are some of the examples of this in VC. What we report here is that in the majority of cases the money for both comes from outside the UK. Our belief is that UK investors should be making up – and taking home – more of the pie."

In plain words: UK science attracts global capital, but British investors are largely watching from the sidelines while overseas buyers collect the returns.

Molloy sharpened the point in a statement. "The pattern this year is clear: UK science attracts expert global capital, but we are missing an opportunity to see returns recycled in our own ecosystem, because too few British investors are taking part," he said.

What does the BIA want from government?

The fix, according to Molloy, runs through policy. He called on the government to create the right environment through incentives so UK biotechs can access the financing they need to grow.

"Government can enable UK biotech companies to make the most of that increased investment and drive economic activity in the UK, if they have preferential access to UK R&D infrastructure and are supported by a tax system, with enhanced R&D tax credits and incentives for reinvestment at its core," Molloy said.

The so-what is straightforward: 2026's record £2.8bn proves UK biotech can win global capital. Whether British investors — and the UK treasury — capture a fair share of that value depends on whether R&D tax credits and reinvestment incentives arrive before the next wave of exits does.